WEBULL
News
VTYX
7.74
+0.65%
0.05
Weekly Report: what happened at VTYX last week (1208-1212)?
Weekly Report · 4d ago
Piper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)
TipRanks · 12/09 11:57
Weekly Report: what happened at VTYX last week (1201-1205)?
Weekly Report · 12/08 09:41
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/04 21:05
Wells Fargo Remains a Buy on Ventyx Biosciences (VTYX)
TipRanks · 12/03 12:48
Ventyx Biosciences: Strategic Adjustments and Expert Appointments Justify Buy Rating
TipRanks · 12/02 17:15
Promising Developments in Ventyx Biosciences’ Clinical Trials Support Buy Rating
TipRanks · 12/02 17:15
Ventyx Biosciences appoints Mark McKenna as strategic advisor
TipRanks · 12/02 12:11
Ventyx Biosciences provides update on ongoing Phase 2 study of VTX2735
TipRanks · 12/02 12:10
Ventyx Pushes Heart Drug Trial Results to 2026 to Test New "Once-Daily" Pill, Taps Heavyweight Advisors, Including CEO Behind $11B Merck Deal
Benzinga · 12/02 12:07
VENTYX PROVIDES CLINICAL AND CORPORATE UPDATES
Reuters · 12/02 12:02
VENTYX BIOSCIENCES INC: REVISING GUIDANCE FOR TOPLINE DATA RELEASE FROM INTERIM ANALYSIS OF PHASE 2 RP TRIAL TO Q1 2026
Reuters · 12/02 12:02
Institutional owners may ignore Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) recent US$77m market cap decline as longer-term profits stay in the green
Simply Wall St · 12/02 10:13
Ventyx Provides Clinical and Corporate Updates
Barchart · 12/02 06:02
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset
Seeking Alpha · 12/01 19:34
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
Benzinga · 12/01 18:45
Ventyx Biosciences to Join Piper Sandler Annual Healthcare Conference
Reuters · 12/01 12:02
Weekly Report: what happened at VTYX last week (1124-1128)?
Weekly Report · 12/01 09:39
Weekly Report: what happened at VTYX last week (1117-1121)?
Weekly Report · 11/24 09:41
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
NASDAQ · 11/18 16:42
More
Webull provides a variety of real-time VTYX stock news. You can receive the latest news about Ventyx Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.